- Home
- Equipment
- usa california
- targeted boron drugs
Show results for
Refine by
Targeted Boron Drugs Equipment Supplied In Usa California
14 equipment items found
by:TAE Life Sciences (TLS) based inFoothill Ranch, CALIFORNIA (USA)
TAE Life Sciences is committed to developing a portfolio of novel targeted boron drugs to expand the application of BNCT to other cancer types and to provide even better outcomes for indications historically treated with Boronophenylalanine (BPA), a boron delivery ...
Manufactured by:Verge Genomics based inSouth San Francisco, CALIFORNIA (USA)
The breadth and depth of our pipeline demonstrates the power of the ConVERGEMplatform. All pipeline programs have been discovered and developed on our proprietary platform. ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CytomX is developing CX-2009, a Probody drug conjugate (PDC) conjugated with DM4, a highly potent cytotoxic drug, targeting CD166, also known as ALCAM. CD166 is a molecule widely and highly expressed on solid tumor cells and previously considered “undruggable” given its expression on normal tissues. In preclinical studies, Probody drug conjugates targeting CD166, have led to ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Allosteric modulators are an emerging class of orally available small molecule therapeutic agents that may offer a competitive advantage over classical ...
Manufactured by:Bio-Rad Laboratories, Inc. (Antibodies) based inHercules, CALIFORNIA (USA)
Antibodies for bioanalysis and drug monitoring of adalimumab and biosimilars. Develop highly selective and sensitive PK and ADA assays for adalimumab (Humira) using our range of ready-made anti-idiotypic antibodies. Highly specific to adalimumab or the adalimumab-TNFα complex. Fully human surrogate positive control or calibrator. Sequence defined, well characterized reagents with secure ...
by:TAE Life Sciences (TLS) based inFoothill Ranch, CALIFORNIA (USA)
Gordon Locher first proposed Boron Neutron Capture Therapy (BNCT) in 1936. Clinical investigation and treatments were first introduced in the USA in the 1950s and showed promising results. Historically, BNCT clinical studies have been carried out using boronophenylalanine (BPA) and neutrons derived from the core of a nuclear reactor. While the clinical outcomes have been encouraging, the ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
Probody therapeutics are designed to outsmart cancer by exploiting the unique conditions of the tumor microenvironment to more effectively localize treatment to the tumor, while limiting activity in healthy tissues. These novel therapies are designed to take advantage of high levels of protease activity in the tumor microenvironment. Their target-binding regions are masked to limit activity ...
by:Valo Health, Inc. based inBoston, MASSACHUSETTS (USA)
Opal is the first end-to-end integrated drug discovery & development platform. Traditional, linear approaches to target discovery and drug development have created sub-optimized systems that are intrinsically disintegrated and ...
Manufactured by:Molecular Devices, LLC. based inSan Jose, CALIFORNIA (USA)
Organoids are derived from biopsies and tissues sampled from patients or subjects (usually termed Patient-Derived Organoids, or PDOs). PDOs are self-organising cell structures that mimic the tissue or organ from which they are derived – they are often termed ‘mini-organs’. ...
Manufactured by:Senti Biosciences based inSouth San Francisco, CALIFORNIA (USA)
Senti Bio has established, and continues to scale, a powerful Design-Build-Test-Learn development engine to generate our therapeutic gene circuits. Unique to Senti Bio’s approach is the speed, quantity and quality of the multiple types of gene circuits designed, resulting in thousands of gene circuits engineered to date. Senti Bio believes that this approach to programming gene circuits is ...
Manufactured by:Qualigen Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
Our RAS-F portfolio includes lead and back-up small molecules that suppress the interaction of endogenous RAS with c-RAF, upstream of the KRAS, HRAS, and NRAS effector pathways. This potentially enables a differentiated, RAS-targeted strategy for inhibiting the MAPK, PI3K, and TOR pathways that are implicated in cancer cell proliferation, survival, and differentiation (see figure). RAS itself ...
Manufactured by:Ardigen based inKraków, POLAND
Bioinformatics Analysis & Drug Discovery in the era of Artificial Intelligence. The digital CRO team brings together scientists and engineers with diverse skill sets, ranging from biology and chemistry to statistics and machine learning. We work with both small startups and big pharmas to leverage digital power in order to enable the development of new therapies. We contribute to the entire ...
Manufactured by:Organovo Holdings Inc. based inSan Diego, CALIFORNIA (USA)
Architecture of ExVive™ 3D Bioprinted Human Liver Tissue with distinct hepatocellular (HC) and non-parenchymal cell (NPC) compartments. The automated bioprinting process results in scalable tissues, with tight control of the composition and ...
Manufactured by:EntroGen, Inc. based inWoodland Hills, CALIFORNIA (USA)
Isocitrate dehydrogenase 1 and 2 (IDH1/2) are key enzymes in cellular metabolism, epigenetic regulation, redox states, and DNA repair. Mutations in IDH1/2 can lead to the development and/or progression of various types of cancer including secondary glioblastomas and acute myeloid leukemias (AML). IDH1/2 mutations are linked to abnormal histone and DNA methylation which may cause altered stem ...